Lymphoma | What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma
Research To Practice | Oncology Videos · Dr. Neil Love
January 16, 20252h 0m
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:
- Introduction (0:00)
- Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17)
- Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51)
- CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01)
- Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46)
- Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44)
CME information and select publications